Bruce Taillon, formerly the director of healthcare business development at Roche's 454 Life Sciences division, is now the head of global technology business development at Enzo Life Science. While at 454, Taillon helped develop the company's next-generation sequencing platforms, including for its potential use in diagnostic assays. He also has experience leading R&D teams in the areas of genomics, proteomics, and drug development.
People in the News
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.